Evidence map›Paper›PMID 28955775›Full record

ArticleBiochemistry and biophysics reports2017

Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells.

Kei Saito, Tohru Fujiwara, Urara Ota, Shunsuke Hatta, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Masahiro Ishizuka and 2 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04542850 nacompletednot on this mapstarted 2020, after this paper: background citation

An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19)

TypeinterventionalSponsorRoyal College of Surgeons in Ireland - Medical University of BahrainRan2020 to 2021Enrolled15ConditionsSARS-CoV 2, COVID-19Arms5-ALA-Phosphate + SFC (5-ALA + SFC)
NCT04854876 nawithdrawnnot on this mapstarted 2021, after this paper: background citation

An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against SARS-CoV-2 Virus Infection

TypeinterventionalSponsorRoyal College of Surgeons in Ireland - Medical University of BahrainRan2021 to 2021Enrolled0ConditionsSARS-COV 2, Covid19Arms5-ALA-Phosphate + SFC (5-ALA+SFC)
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Iron Metabolism in Cancer.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kei SaitoDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohru FujiwaraDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Urara OtaSBI Pharmaceuticals Co., Ltd., Tokyo, Japan.
Shunsuke HattaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Satoshi IchikawaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masahiro KobayashiDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoko OkitsuDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Noriko FukuharaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yasushi OnishiDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masahiro IshizukaSBI Pharmaceuticals Co., Ltd., Tokyo, Japan.
Tohru TanakaSBI Pharmaceuticals Co., Ltd., Tokyo, Japan.
Hideo HarigaeDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JPSBI Pharmaceuticals (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-Aminolevulinic acid (ALA) is a precursor for the biosynthesis of porphyrins and heme. Although the oral administration of ALA has been widely applied in clinical settings, the dynamics of its absorption, metabolism, and excretion within enterocytes remain unknown. In this study, after enterocytic differentiation, Caco-2 cells were incubated with 200 µM ALA and/or 100 µM sodium ferrous citrate (SFC) for up to 72 h. Both ALA and the combination of ALA and SFC promoted the synthesis of heme, without affecting the expression of genes involved in intestinal iron transport, such as

Indexed as

5-Aminolevulinic acidALA, 5-aminolevulinic acidALAS2, 5-aminolevulinic acid synthase 2Bach1Caco-2 cellChIP, chromatin immunoprecipitationCSA, congenital sideroblastic anemiaDMT1, divalent metal transporter 1FPN, ferroportinHeme oxygenase 1HO-1, heme oxygenase 1PP IX, protoporphyrin IXRT-PCR, reverse transcription polymerase chain reactionSFC, sodium ferrous citrate

Identifiers

PMID28955775
PMCPMC5614713
OpenAlexW2734647943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.